These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 16281425)
1. How FDA currently makes decisions on clinical studies. Temple R Clin Trials; 2005; 2(4):276-81; discussion 364-78. PubMed ID: 16281425 [No Abstract] [Full Text] [Related]
2. [Info-congress. COPERNICUS and Val-HEFT studies]. Kulbertus H Rev Med Liege; 2000 Nov; 55(11):1018-20. PubMed ID: 11195705 [No Abstract] [Full Text] [Related]
3. [Sartan as a new therapy option. When heart failure patients cannot tolerate an ACE inhibitor]. MMW Fortschr Med; 2002 Oct; 144(40):49. PubMed ID: 12440300 [No Abstract] [Full Text] [Related]
4. Lessons learned from the valsartan- heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure. Cohn JN Am J Cardiol; 2002 Nov; 90(9):992-3. PubMed ID: 12398968 [No Abstract] [Full Text] [Related]
10. [Treatment of heart failure: an update]. Sinagra G; Perkan A; Cherubini A; Salvatore L; Di Lenarda A Ital Heart J Suppl; 2002 Jul; 3(7):691-7. PubMed ID: 12187629 [TBL] [Abstract][Full Text] [Related]
11. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Krum H; Carson P; Farsang C; Maggioni AP; Glazer RD; Aknay N; Chiang YT; Cohn JN Eur J Heart Fail; 2004 Dec; 6(7):937-45. PubMed ID: 15556056 [TBL] [Abstract][Full Text] [Related]
12. VALIANT trial results support use of valsartan in acute myocardial infarction. Cardiovasc J S Afr; 2004; 15(1):45, 47. PubMed ID: 15095754 [No Abstract] [Full Text] [Related]
13. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075 [TBL] [Abstract][Full Text] [Related]
14. Angiotensin II type 1 receptor blockers and congestive heart failure. Auer JW; Berent R; Eber B Circulation; 2001 Oct; 104(15):E82. PubMed ID: 11591633 [No Abstract] [Full Text] [Related]
15. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. Tepper D Congest Heart Fail; 2002; 8(1):57-8. PubMed ID: 11821630 [No Abstract] [Full Text] [Related]
16. Implications of recent clinical trials for heart failure performance measures. Executive Council Of The Heart Failure Society Of America J Card Fail; 2004 Feb; 10(1):4-5. PubMed ID: 14966767 [No Abstract] [Full Text] [Related]
17. Valsartan in chronic heart failure. Campbell DJ N Engl J Med; 2002 Apr; 346(15):1173-4. PubMed ID: 11951863 [No Abstract] [Full Text] [Related]
18. Valsartan in chronic heart failure. Forfar JC; Munir S N Engl J Med; 2002 Apr; 346(15):1173-4. PubMed ID: 11951862 [No Abstract] [Full Text] [Related]
19. [Changing the paradigm: valsartan-inhibitor of neprilysin, a new dual-acting drug for arterial hypertension and heart failure]. Galve E; Casas-Masnou G; García-Dorado D Hipertens Riesgo Vasc; 2015; 32(1):1-5. PubMed ID: 26179851 [No Abstract] [Full Text] [Related]
20. Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats. Kalender B; Oztürk M; Tunçdemir M; Uysal O; Dagistanli FK; Yegenaga I; Erek E Acta Histochem; 2002; 104(2):123-30. PubMed ID: 12086332 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]